Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Incretin-based therapies
8 evidence topics · 7 sources
FDA-approved indication and dosage: semaglutide 2.4 mg injection for noncirrhotic MASH
ESSENCE part 1 primary end points: planned interim analysis of the first 800 patients at week 72
AASLD update to the practice guidance on semaglutide: indication, patient selection, and cirrhosis
AASLD update to the practice guidance on semaglutide: combination with resmetirom
ADA Standards of Care recommendations 4.26 and 4.27a: GLP-1 RA and dual GIP and GLP-1 RA in adults with type 2 diabetes and MASLD
“In adults with type 2 diabetes, MASLD, and overweight or obesity, consider using a glucagon-like peptide 1 receptor agonist (GLP-1 RA) with demonstrated benefits in MASH A or a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA with potential benefits in MASH B for the treatment of obesity as an adjunctive therapy to lifestyle interventions for weight loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is preferred for glycemic management due to beneficial effects on MASH. A Pioglitazone B or a dual GIP and GLP-1 RA B can be considered for glycemic management due to potential beneficial effects on MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Semaglutide is currently the only glucose-lowering or obesity medication that is FDA approved for the treatment of MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EASL-EASD-EASO guideline recommendations on GLP-1 receptor agonists, issued while the semaglutide phase 3 trial was ongoing
AASLD practice guidance statement on semaglutide for its approved indications, issued before any GLP-1 RA was approved for NASH
“Although several GLP-1RAs are approved for treatment of T2DM, none has been approved for treatment of NASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Semaglutide can be considered for its approved indications (T2DM/obesity) in patients with NASH as it confers a cardiovascular benefit and improves NASH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tirzepatide: SYNERGY-NASH phase 2 trial in MASH with F2 or F3 fibrosis, 190 randomized participants with missing week 52 biopsies imputed
“We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote